Artegraft, Inc. was incorporated in January, 1993, upon the divestiture of the bovine vascular graft business from Johnson & Johnson.
Artegraft was the first vascular graft approved by the FDA (1970) and has been in continuous clinical use for over 40 years. Available in lengths from 15 to 50cm and in 6, 7 and 8mm diameters, Artegraft is approved for use, distal to the aorta, for segmental bypass, arterial replacement, patch graft, femoropopliteal bypass when the patient’s saphenous is absent or inadequate, but is predominantly used as a hemodialysis graft. Artegraft is a Class III, life-sustaining implantable medical device.
Artegraft is positioned in the market as a biological alternative to synthetic grafts, particularly ePTFE, a thermoplastic that was never designed to be punctured 312 times per year as a hemodialysis graft. Artegraft's natural collagen matrix, as well as its surgical versatility and compliance, has proven long-term patency advantages over ePTFE and other synthetic graft materials. Artegraft is also positioned as an alternative to a non-viable autogenous fistula. Think of it as a Fistula in a Bottle™.